Download MendeleyDiscovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: Optimization of kinase selectivity and pharmacokinetics.
Hornberger, K.R., Chen, X., Crew, A.P., Kleinberg, A., Ma, L., Mulvihill, M.J., Wang, J., Wilde, V.L., Albertella, M., Bittner, M., Cooke, A., Kadhim, S., Kahler, J., Maresca, P., May, E., Meyn, P., Romashko, D., Tokar, B., Turton, R.(2013) Bioorg Med Chem Lett 23: 4511-4516
- PubMed: 23856049
- DOI: https://doi.org/10.1016/j.bmcl.2013.06.054
- Primary Citation of Related Structures:
4L53 - PubMed Abstract:
The kinase selectivity and pharmacokinetic optimization of a series of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1 is described. The intersection of insights from molecular modeling, computational prediction of metabolic sites, and in vitro metabolite identification studies resulted in a simple and unique solution to both of these problems. These efforts culminated in the discovery of compound 13a, a potent, relatively selective inhibitor of TAK1 with good pharmacokinetic properties in mice, which was active in an in vivo model of ovarian cancer.
Organizational Affiliation:
OSI Pharmaceuticals LLC, 1 Bioscience Park Drive, Farmingdale, NY 11735, USA. keith.hornberger@boehringer-ingelheim.com
